SARS-CoV-2 Spike Trimerbody could represent a therapeutic option for COVID-19.

14-10-2021

We are glad to report that in a recently published EMBO Journal paper “Neutralization of SARS-CoV-2 by highly potent, hyperthermostable, and mutation-tolerant nanobodies” (https://doi.org/10.15252/embj.2021107985) the authors suggest that a Trimerbody against the receptor-binding domain (RBD) of the SARS-CoV-2 Spike protein could represent a therapeutic option for COVID-19. Compared to the parental nanobody moieties, Trimerbody impressively enhances the avidity against the SARS-CoV-2 Spike protein and block the infectious capacity of the virus. Consequently, theTrimerbody increasesthe blocking potency by a very large factor (more than 300 fold) meaning that Nanobodies that neutralize as monomers greatly benefited from the Trimerbody configuration. This great gain can be explained by enhanced avidity accelerating association and impeding dissociation. Overall, these results indicate that the generation of a Spike specific Trimerbody could represent a treatment option for COVID-19.

EMBO Journal is one of the most renowned worldwide molecular biology publications.

Latest News

SARS-CoV-2 Spike Trimerbody could represent a therapeutic option for COVID-19.
14-10-2021

We are glad to report that in a recently published EMBO Journal...

"Tumor-targeted costimulatory trimerbodies for cancer Immunotherapy”- A brief discussion with Juan Perez Villar, CEO, LEADARTIS.
07-06-2021

...

Diario ABC España y Cadena Cope: Investigadores crean un nuevo anticuerpo antitumoral más eficaz
01-06-2021

El director de la unidad de inmunoterapia del cáncer del Instituto de Investigación del Hospital...